

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_81092
Title of the Manuscript:	Length of hospital stay and Oseltamivir in mild or moderate degree COVID-19 patients in North Sumatra, Indonesia.
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalprijournal.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The article deals with an important topic and concludes on the effectiveness of the medication Oseltamivir in the treatment of covid-19. The authors' conclusion: " Length of hospital stay of mild and moderate degree COVID-19 patients may be shortened with the use of oseltamivir, " is very interesting and can serve as a guide for other health services that provide medical assistance to patients with covid 19.	Thank you for the comments.
Minor REVISION comments	At the end of the introduction the authors report: " Since publication of the report, there were several changes on guidelines especially on recommendations, access and availability of antivirals for COVID-19 [5]. According to the COVID-19 Management Guidelines, the antivirals used for the treatment of mild to moderate degrees of COVID-19 are Oseltamivir, Favipiravir, Remdesivir, and Lopinavir/Ritonavir. " At the present time, there are new guidelines that include new drugs and exclude old drugs used in the treatment of covid19. I suggest authors update this topic with a small paragraph or table, since this article will be published now in the year 2022.	Additional references and sentences were added in "Introduction" (up to date as of February 16, 2022).
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	